217 related articles for article (PubMed ID: 8619540)
1. The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
Nutt JG; Holford NH
Ann Neurol; 1996 May; 39(5):561-73. PubMed ID: 8619540
[TBL] [Abstract][Full Text] [Related]
2. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
[TBL] [Abstract][Full Text] [Related]
3. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
Fabbrini G; Mouradian MM; Juncos JL; Schlegel J; Mohr E; Chase TN
Ann Neurol; 1988 Sep; 24(3):366-71. PubMed ID: 3228270
[TBL] [Abstract][Full Text] [Related]
4. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
[TBL] [Abstract][Full Text] [Related]
5. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
Mouradian MM; Juncos JL; Fabbrini G; Schlegel J; Bartko JJ; Chase TN
Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
Cedarbaum JM
Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of levodopa.
Nutt JG
Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of dyskinesias in Parkinson's disease.
Mouradian MM; Heuser IJ; Baronti F; Fabbrini G; Juncos JL; Chase TN
Ann Neurol; 1989 May; 25(5):523-6. PubMed ID: 2774496
[TBL] [Abstract][Full Text] [Related]
9. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
Mouradian MM; Heuser IJ; Baronti F; Chase TN
Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
[TBL] [Abstract][Full Text] [Related]
10. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
McColl CD; Reardon KA; Shiff M; Kempster PA
Mov Disord; 2002 Nov; 17(6):1227-34. PubMed ID: 12465061
[TBL] [Abstract][Full Text] [Related]
11. Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.
Zappia M; Colao R; Montesanti R; Rizzo M; Aguglia U; Gambardella A; Oliveri RL; Quattrone A
Ann Neurol; 1997 Aug; 42(2):245-8. PubMed ID: 9266736
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the response to levodopa during the first 4 years of therapy.
Nutt JG; Carter JH; Lea ES; Sexton GJ
Ann Neurol; 2002 Jun; 51(6):686-93. PubMed ID: 12112073
[TBL] [Abstract][Full Text] [Related]
13. [Diurnal worsening in Parkinson patients treated with levodopa].
Piccini P; Del Dotto P; Pardini C; D'Antonio P; Rossi G; Bonuccelli U
Riv Neurol; 1991; 61(6):219-24. PubMed ID: 1813974
[TBL] [Abstract][Full Text] [Related]
14. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
Harder S; Baas H
Clin Pharmacol Ther; 1998 Aug; 64(2):183-91. PubMed ID: 9728899
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of levodopa-induced dyskinesia.
Nutt JG
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S160-4; discussion S164-6. PubMed ID: 10762144
[TBL] [Abstract][Full Text] [Related]
16. Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease.
Kishore A; Popa T; Velayudhan B; Joseph T; Balachandran A; Meunier S
Brain; 2012 Jul; 135(Pt 7):2074-88. PubMed ID: 22609619
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal study of the motor response to levodopa in Parkinson's disease.
Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
[TBL] [Abstract][Full Text] [Related]
18. Treating motor fluctuations with controlled-release levodopa preparations.
Koller WC; Pahwa R
Neurology; 1994 Jul; 44(7 Suppl 6):S23-8. PubMed ID: 8047257
[TBL] [Abstract][Full Text] [Related]
19. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathophysiologic aspects of late levodopa failure.
Poewe W
Neurology; 1993 Dec; 43(12 Suppl 6):S28-30. PubMed ID: 8264908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
